Luveltamab tazevibulin
- Generic Name
- Luveltamab tazevibulin
- Drug Type
- Biotech
- Background
Luveltamab tazevibulin, formerly known as STRO-002, is novel homogeneous folate receptor alpha (FolRα) targeting antibody-drug conjugate. It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer).
Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age with Relapsed/Refractory CBFA2T3::GLIS2 AML
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Sutro Biopharma, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06679582
- Locations
- 🇺🇸
Childrens Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Childrens National Hospital, Washington, District of Columbia, United States
🇺🇸Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States
Study to Investigate Luveltamab Tazevibulin in Adults with Advanced or Metastatic Non-small Cell Lung Cancer
- Conditions
- Lung CancerLung Cancer Non-Small Cell Stage IIIBLung Cancer MetastaticLung Cancer, Non-small CellLung Cancer, Nonsmall CellLung Cancer Non-small Cell Stage IV
- Interventions
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Sutro Biopharma, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT06555263
- Locations
- 🇺🇸
Tampa General Hospital, Tampa, Florida, United States
🇺🇸HealthPartners Cancer Research Center, St. Paul, Minnesota, United States
🇺🇸Florida Cancer Specialists, Lake Mary, Florida, United States
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
- Conditions
- Ovarian CancerEpithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal CancerPlatinum-resistant Ovarian Cancer
- Interventions
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Sutro Biopharma, Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT05870748
- Locations
- 🇺🇸
Texas Oncology, Dallas, Texas, United States
🇺🇸Ohio State University Center, Columbus, Ohio, United States
🇺🇸Baptist Health South Florida (BHSF) - Miami Cancer Institute, Miami, Florida, United States
A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
- Conditions
- Ovarian CancerOvarian CarcinomaOvary CancerFallopian Tube CancerPrimary Peritoneal Carcinoma
- Interventions
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Sutro Biopharma, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT05200364
- Locations
- 🇺🇸
University of South Florida,, Tampa, Florida, United States
🇺🇸Thomas Jefferson University, Philadelphia, Pennsylvania, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
- Conditions
- Endometrioid AdenocarcinomaOvarian CancerOvarian CarcinomaPrimary Peritoneal CarcinomaOvary CancerEndometrial CancerFallopian Tube Cancer
- Interventions
- First Posted Date
- 2018-11-20
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Sutro Biopharma, Inc.
- Target Recruit Count
- 136
- Registration Number
- NCT03748186
- Locations
- 🇺🇸
Miami Cancer Institue, Baptist Health South Florida, Miami, Florida, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
🇺🇸Minnesota Oncology Hematology, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.